Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05029063 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters

Study acronym: TRIM-Line
StatusRecruiting
PhasePhase 3
Started2022-10-05
View on ClinicalTrials.gov ↗

Amendment history

2025-07-03
minor
Study Status, Contacts/Locations v5
Study sites7→11
2023-09-27
minor
Study Status, Outcome Measures, Eligibility, Contacts/Locations v4
Study sites2→7
Eligibility criteria+1 characters
[...] ce for >72 hours Patient requires anticoagulation for other indicationindications Concomitant use of dual antiplatelet therapy Major bleeding [...]
Secondary endpointsdetails revised at 1 of 17 entries
2023-05-30
minor
Study Status, Contacts/Locations v3
Study sites1→2
2023-01-13
minor
Study Status, References v2
2022-10-01
notable
Not Yet Recruiting→Recruiting Study Identification, Study Status, Eligibility, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2025-09→2026-12
Completion date2026-09→2027-12
Start date2021-09→2022-10-05
Study sites0→1
Eligibility criteria-40 characters
[...] f cancer and a CVC inserted in the last 72 hours. Exclusion Criteriacriteria: CVC in place for >72 hours Patient requires anticoagulatio [...] t, ketoconazole, itraconazole, posaconazole, or ritonavir). PregnancyKnown (documentation of use of effective contraception if sexually activepregnancy or negativeplan B-to Hcgbecome required)pregnant in next 3 months Severe renal insufficiency (Creatinine clearance <30 mL/min [...] ) in the previous 3 months Documented severe liver disease (ege.g., acute clinical hepatitis, chronic active hepatitis or cirrho [...] penia (platelet count < 50x 109/L) in the previous 3 months [...]
2021-08-25
minor
Original filing
The purpose of the full trial is to determine the efficacy and safety of prophylactic dose rivaroxaban to prevent VTE among cancer patients with CVC.
Trial Details
NCT Number NCT05029063
Lead Sponsor Ottawa Hospital Research Institute
Conditions Venous Thromboembolism, Cancer
Enrollment 1,828 participants
Start Date 2022-10-05
Primary Completion 2026-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-07-09